SEARCH

SEARCH BY CITATION

References

  • 1
    Blomback B (1996) Fibrinogen and fibrin – proteins with complex roles in haemostasis and thrombosis. Thromb Res 83, 175.
  • 2
    Laudano AP & Doolittle RF (1978) Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers. Proc Natl Acad Sci USA 75, 30853089.
  • 3
    Fowler WE, Hantgan RR, Hermans J & Erickson HP (1981) Structure of the fibrin protofibril. Proc Natl Acad Sci USA 78, 48724876.
  • 4
    Weisel JW, Veklich Y & Gorkun O (1993) The sequence of cleavage of fibrinopeptides from fibrinogen is important for protofibril formation and enhancement of lateral agregation in fibrin clots. J Mol Biol 232, 285297.
  • 5
    Weisel JW (1986) Fibrin assembly. Lateral aggregation and the role of the two pairs of fibrinopeptides. Biophys J 50, 10791093.
  • 6
    Spraggon G, Everse SJ & Doolittle RF (1997) Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature 389, 455462.
  • 7
    Gutsche CD (1998) Calixarenes Revisited. The Royal Society of Chemistry, Cambridge.
  • 8
    Vicens J, Harrowfield J & Baklouti L (2007) Calixarenes in the Nanoworld. Springer, Dordrecht.
  • 9
    Casnati A, Sansone F & Ungaro U (2003) Peptido- and glycocalixarenes: playing with hydrogen bonds around hydrophobic cavities. Acc Chem Res 36, 246254.
  • 10
    Cherenok S, Vovk A, Muravyova I, Shivanyuk A, Kukhar V, Lipkowski J & Kalchenko V (2006) Calix[4]arene alpha-aminophosphonic acids: asymmetric synthesis and enantioselective inhibition of an alkaline phosphatase. Org Lett 8, 549552.
  • 11
    Da Silva E, Lazar AN & Coleman AW (2004) Biopharmaceutical applications of calixarenes. J Drug Deliv Sci Technol 14, 320.
  • 12
    Rodik RV, Boyko VI & Kalchenko VI (2009) Calixarenes in bio-medical researches. Curr Med Chem 16, 16301655.
  • 13
    de Fatima A, Fernandes SA & Sabino AA (2009) Calixarenes as new platforms for drug design. Curr Drug Discov Technol 6, 151170.
  • 14
    Hwang KM, Qi YM, Liu SY, Lee TC, Choy W & Chen J (1995) Antithrombotic treatment with calix(n)arene compounds, US Patent 5,409,959.
  • 15
    DA Silva E, Ficheux D & Coleman AW (2005) Anti-thrombotic activity of water-soluble calix[n]arenes. J Incl Phenom Macrocycl Chem 52, 201206.
  • 16
    Jebors S, Fache F, Balme S, Devoge F, Monachino M, Cecillon S & Coleman AW (2008) Designer amphiphiles besed on para-acl-calix[8]arenas. Org Biomol Chem 6, 319329.
  • 17
    Kalchenko OI, Lipkowski J, Nowakowski R, Kalchenko VI, Visotsky MA & Markovsky LN (1997) Studies of the behaviour of some phosphorus contained calix[n]arenes in condition of reversed phase high performance liquid chromatography. J Chromatogr Sci 35, 4955.
  • 18
    Kalchenko OI, Perret F & Coleman AW (2001) A comparative study of the determination of the stability constants of inclusion complexes of p-sulfonatocalix[4]arene with amino acids by RP-HPLC and 1H NMR. J Chem Soc Perkin Trans 2, 258263.
  • 19
    Casnati A, Sartori A, Pirondini L, Bonetti F, Pelizzi N, Sansone F, Ugozzoli F & Ungaro R (2006) Calix[4]arene Anion Receptors Bearing 2,2,2-trifluoroethanol Groups at The Upper Rim. Supramol Chem, 18, 199218.
  • 20
    Vovk AI, Kalchenko VI, Cherenok SO, Kukhar VP, Muzychka OV & Lozynsky MO (2004) Calix[4]arene methylenebisphopshonic acids as calf intestine phosphatase inhibitors. Org Biomol Chem 2, 31623166.
  • 21
    Varetskaya TV (1960) Microheterogeneity of fibrinogen. Cryofibrinogen Ukr Biokhim Zhurn 32, 1324.
  • 22
    Belitser VA, Varetskaja TV & Malneva GV (1968) Fibrinogen-fibrin interaction. Biochim Biophys Acta 154, 376.
  • 23
    Lugovskoi EV, Makogonenko EM, Chudnovets VS, Derzskaya SG, Gogolinsikaja GK, Kolesnikova IN, Bukhanevich AM & Komisarenko SV (1991) The study of fibrin polymerization with monoclonal antibodies. Biomed Sci 2, 249296.